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Abstract 
This study follows four large U.S. pharmaceutical manufacturers through periods prior, during, 
and post major U.S. healthcare legislation. The focus of the study is to understand how top 
management’s attention is affected by industry legislation. Using 18 years of letters to 
shareholders from four U.S. pharmaceutical companies from 2001 to 2018, I analyzed the textual 
data three ways using Provalis Research’s Wordstat software. First, I created word frequency 
clouds to identify key words overall and for each period of time before and after legislation. 
Second, using the “extraction” function in Wordstat, I used topic modeling to identify which 
groups of words (or topics) emerged from the application of a standard topic modeling 
algorithm. Finally, I applied pre-developed dictionaries of organizational constructs to the textual 
documents to compare frequencies among these time periods. From these analyses, I identify 
precautions and tactics used by executives of pharmaceutical manufacturers during periods of 
healthcare reform. 
Keywords:  Pharmaceutical manufacturers, pharma, topic modeling, healthcare reform, 
healthcare legislation, run-time, Affordable Care Act (ACA), Medicare Modernization Act 
(MMA), Pfizer, Amgen, Johnson & Johnson, Bristol-Myer Squibb 
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Major Healthcare Legislation: Effects and Reactions by Large U.S. Pharmaceutical 
Manufacturers, 2001-2018 
The United States operates a complex, multifaceted healthcare system, with players both 
public and private, ultimately providing healthcare to the largest economy in the world. 
Currently, the healthcare sector has come under great scrutiny based on affordability, level of 
care, and coverage. Pharmaceutical manufacturers, specifically, play a large role surrounding the 
current political affordability discourse as drug prices in the U.S. continue to rise. Although 
pharmaceutical manufacturers are not the sole entity to blame for drug prices at the pharmacy 
counter, they are the first in the pharmaceutical supply chain and set the beginning price of a 
drug before markups by various other sub-industries.  
As well, the U.S. has a large number of “middleman” entities in its system and inefficient 
insurance companies. Having worked for a year trading and analyzing healthcare securities for 
various healthcare sub-industries, I was able to identify a few “middleman” entities responsible 
for high prices in the U.S. healthcare system.  
 Imagine if textbooks and school supplies went through “middlemen” before being 
purchased by schools. Say a textbook company invests money and years of time creating a 
textbook, but instead of being able to sell it directly to schools, they must sell indirectly to a 
complex network of interconnected companies. For the example’s purpose, let’s imagine there 
are textbook distributors, textbook stores, and textbook price insurance companies. Here, 
roughly, is how all the companies would interact. Basically, textbook price insurance companies 
would decide what books the schools could buy based on negotiated final textbook prices with 
partner textbook distribution companies. In the meantime, textbook distribution companies 
negotiate higher, marked-up prices to distribute textbooks to textbook stores based on the 
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maximum price insurance companies said they would cover/pay. Simultaneously, the textbook 
distributor is negotiating lower textbook prices with textbook manufacturers and searching for 
cheaper, generic textbooks from different manufacturers. Finally, the textbook management 
companies supply the textbooks stores with textbooks it knows insurance companies will cover 
at approximately the price it knows the insurance company is willing to pay.  
 So, what is the point of this complex analogy? By the time a school goes to the textbook 
store to buy the books its insurance company covers, the textbook has already been through two 
middlemen who both marked up the price to the amount the insurance company is willing to pay. 
The result, extremely high prices for textbooks based on negotiations between distributors, 
sellers, and insurance companies. As time goes on, the insurance companies will have to 
continually raise their premiums as the distributors and stores craftily estimate the insurance 
coverage and compute a “sellable price.”  
 Surprisingly, this process is how drugs get to pharmacy counters. Instead of textbook 
distribution companies and textbook sales companies, the entities are pharmacies and pharmacy 
benefits managers who liaison between pharmaceutical manufacturers, pharmacies, hospitals, 
and insurance companies to ultimately determine the final drug cost based on current legislation 
and insurance coverage. Consequently, healthcare reform and legislation change these 
interactions and influence manufacturers and the final drug price. Therefore, understanding the 
interactions between manufacturers and healthcare legislation becomes imperative when 
interpreting the pharmaceutical supply chain. 
 Without having complete power over the final drug price, pharmaceutical manufacturers 
must tread carefully when navigating these complex negotiations. These manufacturers must 
ensure the prices charged for the drugs, which they spend millions or billions on developing, are 
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appealing to private insurance companies and Medicare/Medicaid. Note the pluralization of the 
word prices above, pharmaceutical companies and their partner pharmacy benefits managers 
often negotiate different prices for different insurance companies and Medicare/Medicaid.  
 Adding to pharmaceutical manufacturers’ stress, once a drug hits the market its patent 
only lasts for a finite number of years before large generic manufacturers can launch an identical 
drug at a fraction of the cost without having to incur massive research and development 
investments. Additionally, not all developed drugs, which still cost millions to billions to 
develop, gain FDA approval or are successful, so the costs of these failed drugs must be covered 
by the profits of successful drugs, further inflating the price. When one considers all the factors 
pharmaceutical manufacturers must take into consideration – what drugs to develop, the budget 
for developing drugs, getting FDA approval, how much to sell drugs for, how much failed drug 
investment needs to be recovered by the successful drugs, how long can they be sold, will 
anyone buy or cover the drugs, and will legislation change effect any of the prior factors – the 
strategy and process for manufacturing drugs becomes overwhelmingly complex. 
 Specifically, research and development costs are a differentiating factor between the 
overall healthcare sector and pharmaceutical manufacturers. Compared to the rest of the sector, 
the U.S. pharmaceutical industry spends nearly 15% more on research and development 
annually, as shown on the next page by the “other” category in figure 1. The high proportion of 
R&D costs reflects the highly competitive and complicated nature of the pharmaceutical market 
and is evidence of manufacturers’ need to continually create new drugs. 
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Figure 1: Despite seemingly harsh industry conditions, the pharmaceutical manufacturing industry in the 
U.S. out-performs other areas of the healthcare sector. From: www.ibisworld.com 
 
 Ever since I began trading, studying, and analyzing the healthcare industry and healthcare 
securities for the University of Tennessee, I became fascinated by how pharmaceutical 
manufacturers survive. I have been especially intrigued by certain large manufacturers’ ability to 
adapt to major healthcare reform. The focus of this research is to address this question: What are 
those reactions – actions, attention and considerations – made by these companies across 
legislative changes? 
          To address this research question and analyze manufacturers’ resiliency to legislative 
change, I studied the reactions and behaviors of large pharmaceutical manufacturers during the 
running time after a bill’s proposal/announcement and when the change has been enacted. To 
gleam the best indication of a pharmaceutical manufacturing firm’s reaction and preparation for 
legislative change, I will track what strategies the CEOs were pursuing or no longer pursuing 
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during a bill’s runtime and post enactment phases. I will use three textual analysis approaches to 
compare the focus of executive attention across three time periods. First, I will create word 
frequency clouds to identify key words overall and for each period of time before and after 
legislation. Second, I will use topic modeling to identify which groups of words (or topics) 
emerged from the application of a standard topic modeling algorithm. Finally, I will apply pre-
developed dictionaries of organizational constructs to the textual documents to compare 
frequencies among these time periods. From these analyses, I identify precautions and tactics 
used by executives of pharmaceutical manufacturers during periods of healthcare reform. 
The Medicare Modernization Act (MMA) and the Affordable Care Act (ACA) constitute 
the two largest and most recent legislative changes impacting the U.S. pharmaceutical 
manufacturing industry. Therefore, my study is divided into three distinct phases: pre-MMA, 
post-MMA/pre-ACA, and post ACA. These periods allow for analysis of executive attention 
during the runtime and post legislative periods.  
Author Background 
My experience comes from years of undergraduate study surrounding the healthcare 
sector. Early on, I served as a fund manager specializing in healthcare securities for the Haslam 
College of Business where I researched, pitched, and traded pharmaceutical manufacturing 
companies, insurance companies, and medical device firms. My most memorable experience 
from my time on the fund was acquiring a newly vertically integrated firm in the pharmaceutical 
supply chain world which had just completed a merger. The firm’s future looked bright, but I 
miss predicted the effects of upcoming healthcare legislation, and, at the same time, the 
Affordable Care Act was placed under question nationally by a Texas judge. The legislation and 
the uncertainty surrounding the Affordable Care Act sent the sector through the floor, and my 
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chosen firm’s bright future was flipped on its head. In short, the dramatic change fascinated me 
and caused a newfound curiosity within myself towards these seemingly impossibly complicated 
manufacturing firms.  
In addition to my time as a fund manager, I took technical writing/editing for publication 
classes where I frequently choose to study healthcare in my research. So, as my undergraduate 
time is ending, I wanted to produce one final study on a largely misunderstood and confusing 
sector to determine what really goes on within large pharmaceutical manufacturers. 
Industry Background 
Worldwide, healthcare varies drastically, but our own, in my opinion, holds first place 
regarding complexity, number of players, and coverage issues. We are the largest economy in the 
world and providing coverage on such a large scale undoubtably brings challenges and 
complexity. However, many of these issues have become more prevalent as U.S. citizens struggle 
to pay for their prescriptions, both with insurance and without. 
This study will focus on the brand name pharmaceutical manufacturing industry in 
relation to legislation change. Currently, brand name pharmaceutical manufacturing is a $188.4 
billion industry 3,248 businesses strong. Exporting $44.2 billion worth of drugs in 2019 and 
generating $35 billion in profits, the industry plays a large role in the overall healthcare sector 
(Spitzer, 2019). According to the 2019 IBIS World Report, a few primary drivers for the brand 
name pharmaceutical manufacturing industry are: federal funding to Medicare and Medicaid, the 
median age of the U.S. population, the number of privately insured, and, of course, regulation 
(Spitzer, 2019).  
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Major U.S. Healthcare Legislation 101 
To best understand U.S. pharmaceutical manufacturers’ ability to adapt to healthcare 
change, one will benefit from knowledge of U.S. Healthcare history. Most know U.S. Healthcare 
is a privatized system with public elements (Medicare and Medicaid), but how long has the 
private/public approach really been around? According to Manchikanti, Helm, Benyamin, and 
Hirsch (2017), the history of public United States Healthcare legislation began in 1965 when 
President Lyndon B. Johnson passed Medicare and Medicaid into law. At last, President 
Johnson’s historic act provided government coverage for the poor, needy, and elderly. Now, 
pharmaceutical manufacturers had a new, very large client – the U.S. government.  
Continuing through history, many revisions, additions, and subtractions were passed 
modifying Medicare and Medicaid, and new government programs were added to supplement 
the existing legislative structure. Now, pharmaceutical manufacturers, in conjunction with 
insurance companies and pharmacy benefits managers, were battling to gain the business of both 
the government and American citizens on private insurance. The next notable legislation change 
comes in the 1990s with the Clinton administration. President Bill Clinton, with the help of first 
lady Hillary, enacted the Health Security Act. The act created two new government 
organizations: HIPPA – Health Insurance Portability and Accountability Act – and SCHIP – State 
Children’s Health Insurance Program (Manchikanti et al. 2017). These programs protected 
personal healthcare information and children’s healthcare rights. However, the two largest 
sweeping overhauls to U.S. healthcare have come within the past 20 years.  
Sweeping Change 1: Medicare Modernization Act, 2004-2006 
The next legislative break came in the early 2000s. After the Clinton administration and 
the democrats placed their stamp on healthcare in the 90s, the election of President George W. 
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Bush gave Republicans an opportunity to shape healthcare reform.  At the end of 2003, President 
George W. Bush passed the Medicare Modernization Act (MMA). The act redefined and 
modified existing parts of Medicare and Medicaid but, also, added new ones such as Medicare 
Part D which governs drugs under the Medicare and Medicaid programs. To be clear, Medicare 
and Medicaid only apply to those in the programs. Americans on private insurance are not 
directly affected by Medicare and Medicaid.  
To provide some scale, the MMA’s Part D policy was the most expensive addition to 
Medicare in history at the time of its passage, and the legislation had a two-part goal: increase 
senior citizen access to drugs and control escalating prescription drug prices. Medicare Part D 
alone was estimated to cost between $450 to $750 billion during its first ten years (Balotsky, 
2009). Before launching the industry into the new policy, an integration time was implemented 
(or, as I will refer in this study, run/running time) during 2004 and 2005. The run time measures 
came in the form of drug coupons for senior citizens to provide companies an easy transition 
before the law came into full effect in 2006 (Balotsky, 2009). So, what exactly did 
pharmaceutical manufacturers have to prepare and adapt for to take advantage of the new plan? 
According to Megellas (2006), here are a few major MMA Part D parameters: 
• The Center for Medicaid Services set a tentative monthly premium of $37 ($448 per 
year). 
• Participants have a $250 annual deductible. 
• “For drug costs between $251 and $2250, Medicare and the plan will share 75% of 
the cost and the beneficiary will pay for the remaining 25%.” 
• “For drug costs between $2251 and $5100, the beneficiary is responsible for 100% of 
the cost; this is referred to as the gap or doughnut hole.” 
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• “For drug costs exceeding $5100, Medicare will pay 80%, the plan will pay 15%, and 
the beneficiary will pay 5%.” 
 Now consider yourself a CEO of a large Fortune 500 pharmaceutical manufacturer like 
Amgen. Which price range would you target your drugs to fall under? Well, I suppose the better 
question would be which price range would you not want your drugs to fall under? Obviously, 
the doughnut hole range. While some believed the Medicare Modernization Act was a step in the 
right direction, it does not take an expert to note it caused an ethical dilemma within the 
pharmaceutical supply chain while firms navigated the new legislation.  
 However, while Part D was the major new supplement the MMA added, changes to other 
parts of the bill dramatically affected firms in the pharmaceutical supply chain as well. For 
example, Medicare Part B changes altered the way drugs were sold and acquired via a change in 
government drug reimbursements (Megellas. 2006). The overall answer to the legislation seemed 
instead to target the elderly and take advantage of the new pricing legislation.  
 The American Association of Retired Persons (AARP) monitored drug prices following 
the implementation of the legislation and found the industry may be raising prices of prescription 
drugs. Specifically, drugs used and needed by the elderly. During the first quarter of 2006, AARP 
found 193 prescription drugs commonly used by Americans over 50 years old saw a price 
increase of around 6.2% relative to their prices 12 months prior from pharmaceutical 
manufacturers (Manchikanti et al. 2017). However, manufacturer prices for generic drugs saw 
little price change. Additionally, the participating Part D insurance companies’ policies were 
insufficiently negotiating against climbing prices. For example, the median price increase during 
the same 12-month period for the twenty most popular senior citizen drugs was 3.7% 
(Manchikanti et al. 2017). The Medicare Modernization Act (MMA) had substantial effects on 
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the pharmaceutical supply chain, especially insurance companies and pharmaceutical 
manufacturers, but the actual price containment left much to be desired. 
 So, what was the final result of the change on pharmaceutical manufacturers? By 2007, 
one year after full enactment, manufacturers now had a 39 million strong Medicare Part D 
market to sell drugs to (“Medicare Drug Plans Strong and Growing”). With Medicare Part D, the 
government had inserted itself as a large client into the complex negotiations of the 
pharmaceutical supply chain and caught the eye of many manufacturers hoping to sell new 
drugs.  
Sweeping Change 2: The Affordable Care Act, 2010 
 After a change in political parties occupying the White House, the 2008 presidential 
election put democrats back in charge. Like today, voters a decade ago were concerned with the 
U.S. Healthcare system, and the elected administration was ready to restart and refresh 
government-based healthcare through the Affordable Care Act (ACA). Once implemented into 
law, the ACA was regarded as the largest change to U.S. Medicare ever. According to 
Manchikanti et al (2017), the Affordable Care act had three primary goals: 
1. Increase the number of the insured. 
2. Improve the quality of care. 
3. Reduce the costs of healthcare.  
 The first and third being the most applicable to the U.S. pharmaceutical supply chain, 
especially U.S. pharmaceutical manufacturers. The first increased the size of the government ran 
healthcare market. The total increase to those insured under Medicare and Medicaid came 
primarily through Medicaid expansion (Manchikanti et al. 2017). Medicaid enrollment increased 
by approximately 13 million and Medicare increased by around 7 million, but, according to a 
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2015 RAND Corporation study, nearly 6 million lost their coverage (Manchikanti et al. 2017). 
No legislation is perfect and the ACA “widened the gap between providing patients the 
mechanism of paying for healthcare and actually receiving it (Manchikanti et al. 2017).” More 
specifically, the Affordable Act works well for certain protected classes but falls short for 
working- and middle-class citizens as the level of aid from Medicaid is determined based on 
one’s income level’s proximity to the federal poverty line (Manchikanti et al. 2017). Basically, 
like the MMA’s doughnut hole for drug coverage, the ACA’s doughnut hole is the middle- and 
working-class giving pharmaceutical manufacturers and other healthcare businesses a target 
market and price range for certain classes of the insured.    
 Former President Bill Clinton summarizes the ACA: “so you have got this crazy system 
where all of a sudden, 25 million more people have healthcare and then the people who are out 
there busting it, sometimes 60 hours a week, wind up with their premiums doubled and their 
coverage cut in half. It is the craziest thing in the world (Manchikanti).” Despite the confusion, 
the ACA offers beneficiaries “10 – essential benefits” according to Manchikanti et al.’s (2017) 
study: 
1. Ambulatory patient services 
2. Emergency services 
3. Hospitalization 
4. Maternity and newborn care 
5. Mental health and substance abuse disorder services, including behavioral health 
treatment 
6. Prescription drugs 
7. Rehabilitative and habilitative services and devices 
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8. Laboratory services 
9. Preventive and wellness services and chronic disease management  
10. Pediatric services, including oral and vision care 
Importantly, the ACA covered prescription drugs, and, unlike the MMA, most of the 
ACA’s reach applied to Medicaid, not Medicare, meaning the age demographic under 
government ran healthcare shifted down as Medicaid covers all ages and Medicare being 
reserved for the elderly. So, from a pharmaceutical manufacturer’s perspective, they know the 
government market now has twenty million more insured consumers that are younger and many 
with prescription drug coverage. Surprising to some, expected to others, the ACA did not prevent 
the rise of drug prices; in fact, the ACA escalated the increase in prescription drug pricing 
(Manchikanti et al. 2017). So, what are pharmaceutical manufacturers doing during these periods 
of change other than hiking prices? Is there a method to the madness? What strategies were 
employed to keep pharmaceutical firms successful amidst strong competition and with high risk 
businesses?  
Methods 
To study pharmaceutical companies and their focus during times of legislative change, I 
chose to analyze four large U.S. pharmaceutical manufacturers by running advanced topic 
modeling software over 18 years of letters to shareholders from each firm from 2001 to 2018. I 
elected to analyze letters to shareholders because I wanted to see where CEO’s were shifting 
their focus during periods prior, during (run time), and after large legislative change.  
Content Analysis and Attention-Based View 
Documented in Sonpar and Golden-Biddle’s 2007 academic paper, content analysis is 
useful to identify how executive attention changes over time, according to an ABV or Attention-
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Based View of the firm. Generally, ABV’s goal is to provide information regarding how a firm 
behaves and is based on the premise that an organization or firm’s behavior results from where it 
places its focus or attention (Sonpar & Golden-Biddle, 2007). The flow works like so: a firm’s 
top management’s attention to an issue trickles down influencing the organization’s attention to 
the issue and ultimately results in the firm taking action towards the issue.  
Content analysis and the ABV model were used in a 2006 study of Regional Health 
Authorities (RHA) in the Canadian province of Alberta (Sonpar & Golden-Biddle, 2007). As 
with my own study, many precautions were taken to ensure the accuracy and reliability of the 
content analysis. The study archived all relevant published documents from the RHAs and the 
government. Once archived, the documents were loaded into advanced software and special 
topical dictionaries were compared to each document to identify a larger concept or topic. For 
example, words like promotion, healthy, living, and protection were loaded into a dictionary 
called wellness, so, when the software would see a high level of those words in a document, it 
would mark the document as containing the topic of wellness indicating management’s attention 
to wellness (Sonpar & Golden-Biddle, 2007). Thus, the content analysis using an ABV 
framework establishes causal relationships between certain programmed dictionary words to 
topics.  
Distinct from the RHA study, I located business-specific dictionaries tailored for my 
content analysis software instead of crafting my own (See Appendix 1). To ensure accurate 
information, I edited and created an extensive exclusion dictionary, which kept the software from 
returning topics like the word “the” (See Appendix 3). 
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Brand Name Pharmaceutical Manufacturers Studied 
For my analysis, I chose four of the largest brand name pharmaceutical manufacturers 
based in the U.S: Pfizer, Amgen, Bristol-Myers Squibb, and Johnson & Johnson. To ensure 
accurate results, I gathered annual reports from 2001 to 2018 capturing periods prior, during 
runtime, and after both the Medicare Modernization Act and the Affordable Care Act. 
Figure 2: Depicts major U.S. brand name pharmaceutical manufacturers by increasing market share left 
to right. 
Pfizer Inc. 
According to the IBIS Industry report for brand name pharmaceutical manufacturers 
(Figure 1), research-based Pfizer Inc. is the world’s largest pharmaceutical company and 
conducts most of its business in the U.S. capturing 11.8% of the total U.S. pharmaceutical 
industry’s market (Figure 2). Headquartered in New York with a global research facility network, 
the pharmaceutical giant serves two distinct business segments: innovative health and essential 
health (Spitzer, 2019). Lipitor, Norvasc, and Zoloft are a few recognizable drugs Pfizer currently 
sells. However, Pfizer’s full portfolio of drugs includes vaccines, small molecule medicines, and 
biologics (Spitzer, 2019). Overall, Pfizer has stood the test of time in the U.S. pharmaceutical 
industry since its inception in 1849.  
Amgen Inc. 
The youngest brand name pharmaceutical business in this study, Amgen Inc. specializes 
in developing biopharmaceutical products for human therapeutics (Spitzer, 2019). The 2019 IBIS 
Industry report indicates an industry market share of 9.7% for Amgen. With a human 
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therapeutics focus, Amgen focuses on therapies for oncology/hematology, cardiovascular 
disease, bone health, inflammation, nephrology, and neuroscience (Spitzer, 2019). A few 
recognizable drugs from Amgen include Neulasta, Enbrel, and Prolia. While Amgen sells 
products worldwide, it relies heavily on pharmaceutical distributors for sales within the U.S. 
accounting for 96% domestic sales in 2017 (Spitzer, 2019). Resultingly, Amgen, like the rest of 
the studied firms, has a large exposure to U.S. healthcare legislation.  
Bristol-Myers Squibb 
Another manufacturer who has stood the test of time, Bristol-Myers Squibb is an 
important U.S. name brand pharmaceutical manufacturer. However, unlike the Pfizer and 
Amgen, Bristol-Myers Squibb’s once great market share – the second largest pharmaceutical 
company in the world in 1989 – has since dwindled. Now, the firm only controls 6.9% of the 
U.S. name brand pharmaceutical industry (Spitzer, 2019). Operating solely in 
biopharmaceuticals, the firm’s focus is on cancer treatments. Like Pfizer, Bristol-Myers Squibb 
is headquartered in New York and conducts the majority (56%) of its business domestically. A 
few recognizable drugs from Bristol-Myers Squibb are Eliquis and Opdivo (Spitzer, 2019). 
While Bristol-Myers Squibb may not be leading the industry, it still remains a key player in the 
U.S. today.  
Johnson & Johnson 
Likely the most recognizable brand of the studied firms, Johnson & Johnson currently 
holds the second largest market share of the U.S. pharmaceutical market. Slightly different from 
the rest, Johnson & Johnson is a holding company with over 260 companies under its name. 
However, the entire Johnson & Johnson enterprise can be broken down to three lines of business: 
pharmaceutical, consumer products, and medical devices (Spitzer, 2019). Dissecting its 
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pharmaceutical arm, the firm currently serves six therapeutic areas: immunology, vaccines, 
nervous system disorders, oncology, metabolism and pulmonary hypertension, and 
cardiovascular. A few recognizable drugs from the firm are Remicade, Topamax, and Procrit 
(Spitzer, 2019). Johnson & Johnson, then, is the most diversified company included in the study, 
and its pharmaceutical branch has managed to edge out dedicated pharmaceutical manufacturers.  
Data Analysis 
For my research, I focused on 71 letters to shareholders spanning from 2001 to 2018 from 
four major U.S. pharmaceutical manufacturers (18 letters from each, with the exception of 17 
letters from Bristol-Myers Squibb) to capture where top management’s attention was during a 
given period as outlined in the ABV approach. I utilized my university’s extensive resources to 
find content analysis software (Provalis Research’s QDA Miner and Word Stat programs). I 
undertook three text analysis approaches: word frequencies, topic modeling, and dictionary 
application.  
After all the letters to shareholders and dictionaries were loaded into the program, I chose 
to conduct a few different types of content analyses. For my first analysis, I divided the letters 
into three periods and identified word frequencies for each time period. The word frequencies are 
represented by word clouds from each period; these word clouds represent the most important 
keywords from a given period ranked by frequency per 10,000 words. Second, I used the topic 
modeling algorithm in Wordstat to identify the groups of words or topics for each period group. 
Finally, I overlaid dictionaries previously created in management research (Appendix 1) onto the 
letters from each period as another method to understand and statistically compare the attention 
of top management over these legislative periods.  
The breakdown of the periods studied is shown below:   
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1. Pre-Medicare Modernization Act (2001 – 2003) 
2. Post-Medicare Modernization Act/Pre-Affordable Care Act (2004 – 2009) 
a. First MMA legislative changes went into effect in 2004 and were finalized 
in 2006 
3. Post-Affordable Care Act (2010 – 2018) 
 
Findings & Discussion 
What are the reactions – actions, attention and considerations – made by these companies 
across legislative changes? The areas of focus across the studied periods did change; however, 
the resulting changes from top management were more often alike to shifts in focus rather than 
prominently introducing new focuses or dismissing old ones period to period. For example, 
major words in the word frequency clouds (Figures 3,4,5, and 6 on the following pages) show 
words from period to period gradually coming in and going out of focus, but few prominent 
words in one section disappear all altogether or appear only once. These shifts in focus, then, 
represent attention trade-offs from top management across legislative changes instead of entirely 
new strategic focuses tailored to each change. So, what are these focus-shifts before, during, and 
after legislative change, and what do they tell us about how these companies prepare and adapt to 
changes? 
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Analysis of the Entire Study Period, 2001-2018 
 
Figure 3: Depicts word frequency over entire period studied from letters to shareholders. 
The word frequency analysis in Figure 3 yielded findings for the overall period. Depicted 
above, the overall word frequency cloud shows words which the four firms’ top management 
wrote the most over the date range (2001 – 2018). Note, the larger, more centralized the word the 
more frequent the word arose in the CEOs’ letters to shareholders. Health, care, products, 
medicines, world, and people have been primary focuses of CEOs for the past twenty years, 
which, in turn, tells us the primary focuses of the firms over the time period. Surprisingly, 
strategy and the consumer gleamed relatively little focus from the firms over the period, but the 
larger emphasis on people over consumers implies large pharmaceutical manufacturers see their 
clients as people instead of consumers.  
The topic model produced from the entire data range yielded interesting, surprising 
results. The topics, ranked from greatest attention by management to lowest attention by 
management follow as such (See Appendix 2 for full topic model results): 
1. HIV/AIDS 
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2. Clinical Trials Lung Cancer 
3. Medical Devices 
4. Ownership Culture 
5. Therapeutic Areas: Discovery and Development 
 The topic model informs us that during the entire date range brand name pharmaceutical 
manufacturers focused on producing new therapies/products. During the past twenty years, the 
top two areas of pharmaceutical manufacturer focus were AIDS and lung cancer. These make 
sense as areas of focus for manufacturers as they were, and still are, large areas of need within 
the pharmaceutical community. However, they are not the focus of firms today; the model overall 
shows the scale of the focus for AIDS and lung cancer as they held the most attention from large 
pharmaceutical companies. Additionally, we see the other remedy for preparing for legislative 
change during runtimes from the ownership culture topic. By focusing internally, the firms 
strengthen themselves to be best prepared for an uncertain future.  
Period 1: Pre-Medicare Modernization Act, 2001-2003 
     
Figure 4: Depicts word frequency over years 2001-2003 from letters to shareholders. 
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Period 1 or the Pre-Medicare Modernization Act time period provides a glimpse into 
what the firms were doing before any major healthcare reform was enacted, only the run time 
preparations for the upcoming Medicare Modernization Act are reflected above. Unlike the word 
cloud for the entire period 2001-2018, the attention of CEOs during this period was more 
business centered and internally focused. The words year, company, business, and products 
occurred the most during the period; therefore, in anticipation of legislation, the firms seem to 
prepare themselves by growing their product line and in turn strengthening business. Recall, the 
Medicare Part D provision first rolled out with the Medicare Modernization Act, so the internal 
focus makes since as the firms all wanted to be prepared to take on the new, vast government-
backed Part D plan.  
The topic model falls somewhat in line with the word frequency cloud for this period. 
The topics produced by the content analysis from period one are as follows (See Appendix 2 for 
full topic model results): 
1. Worldwide Sales Operational Growth 
2. Research and Development 
3. Pharmaceutical Company and People 
4. Healthcare 
5. Key Leadership 
6. Food and Drug Administration Patents 
7. Financial Performance/Corporate Governance 
The topics for the first period carry some of the same themes as the word frequency cloud 
but show more specific areas of focus. For example, instead of year and company as the top two 
focuses, the topic model went into more detail informing us the primary focus of management 
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was worldwide sales operational growth. This shows us that the companies were attempting to 
take out an insurance policy, so to speak, during the run time for the Medicare Modernization Act 
by way of strengthening foreign drug sales unaffected by the legislation. Additionally, the topics 
of corporate governance and key leadership strongly indicate a push for internal stability before 
the legislative landscape for drugs changed. 
The topics research and development and Food and Drug Administration patents show a 
second avenue of precaution taken during the time period. Pharmaceutical manufacturers are 
always focused on their drug pipeline and ensuring they have enough upcoming products to take 
place of older ones, but the topics were more defined during this period than the overall analysis. 
Therefore, I am inferring that the companies were ramping up their product lines to ensure sales 
stability/growth during the changing period and to prepare products for the upcoming Medicare 
Part D.  
Overall, the brand name pharmaceutical manufacturers appeared to be cautiously 
optimistic during the run time before the Medicare Modernization Act. First, they focused on 
growing the areas of the business largely unaffected by the change – overseas sales. However, 
their next priorities were to internally strengthen their leadership structure and grow their 
pipeline, areas of focus which help the firms take advantage of both global and domestic sales. It 
seems clear then, that the manufacturers were mitigating future risks during the run time before 
legislation took effect. The manufacturers placed bets on their international abilities and 
strengthening their own leadership and products to fully take advantage of the new legislative 
change.  
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Period 2: Post-Medicare Modernization Act/Pre-Affordable Care Act, 2004-2009 
                 
Figure 5: Depicts word frequency over years 2004-2009 from letters to shareholders. 
The second period’s word frequency cloud shows subtle changes from the prior period 
indicating some post-Medicare Modernization Act changes and evidence of preparations in 
anticipation of the upcoming Affordable Care Act. Words like year, products, and business 
shrank relative to the period one cloud, and words like growth, care, and health grew. The largest 
difference is the change from an overall internal focus to a new overall external growth focus.  
The topic model produced from the letters in period two reflects the main focus of the 
word cloud: growth. Below are the topics, again ranked by most attention from management (See 
Appendix 2 for full topic model results): 
1. Stage Pipeline 
2. Sales Growth 
3. Unmet Medical Disease Areas 
4. Medical Devices 
5. Patients 
6. Research and Development 
7. Company Performance 
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Undoubtably, the manufacturers focused on rapid growth after the enactment of the 
Medicare Modernization Act. The growth focus in the period following the Medicare 
Modernization Act indicates the firms successfully weathered the legislative change and nuances, 
and they now were in full expansion and growth mode. Looking at the topics in context with the 
rest from the period, there is no topic which is not centered around growth and external focuses. 
Overall, it appears after the passage of the Medicare Modernization Act firms expanded as 
rapidly as possible during the brief period of semi-legislative stability.  
 More interesting than the growth focus, the lack of strong internally focused themes and 
attention areas from management is contradictory to the manufacturer’s actions in anticipation of 
the Medicare Modernization Act in the first period. The difference represents a break in 
procedure from the first sweeping legislative change to the second. I hypothesize the firms now 
had recent experience with dealing with large change, and the internal strengthening measures 
taken in preparation for the Medicare Modernization Act were deemed good enough by top 
management to not call for more in anticipation for the Affordable Care Act. Interestingly, the 
firms did not focus abroad in anticipation of the Affordable Care Act like they had done for the 
Medicare Modernization Act. 
Further, the Affordable Care Act, while it was a large change, did not introduce an 
entirely new government drug coverage plan like the Medicare Modernization Act from a 
pharmaceutical manufacturing perspective. Rather, it altered Part D and changed the way 
businesses farther up the supply chain interacted with Part B. Importantly, the focus of the 
Affordable Care Act was to give all Americans access to health insurance. For pharmaceutical 
manufacturers, the change meant more Americans would have health insurance, so it was more 
likely than not that more Americans would buy prescription drugs. With the potential for the 
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Affordable Care Act to grow the number of covered Americans, the focus on growth makes sense 
as it prepares the firms to keep up with the potentially larger market. 
Overall, the run-time preparations of growth and expansion for the Affordable Care Act 
are largely like the post-Medicare Modernization Act adaptations. However, the difference 
between run time preparations for the two bills indicates a lack of faith by the pharmaceutical 
manufacturers for the first sweeping change, but, for the second, the manufacturers had already 
learned to deal with new government drug programs and were more confident in their abilities to 
sell and manufacture drugs.  
Period 3: Post Affordable Care Act, 2010-2018 
              
Figure 6: Depicts word frequency over years 2010-2018 from letters to shareholders. 
The post-Affordable Care Act period’s word frequency cloud yielded a new focus. With 
the firms having prepared and adapted for the Medicare Modernization Act and focused on 
growth in anticipation from the Affordable Care Act, the name brand pharmaceutical 
manufacturers found themselves in a stable legislative environment with no new major changes 
on the horizon. So, what did they do? From the word cloud, it appears top management directed 
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the firm’s attention to a customer focus. However, the apparent new patient focus may not be the 
result of a new adaptation or change in response to the Affordable Care Act; rather, the word 
patients has appeared in every word cloud and has grown with each one. The slowness of the 
patient focus transition, taken into context with the other periods, seems the result of the 
distraction of top management by the legislative pieces created to protect Americans. A 
frustrating phenomenon arises. When the government passes legislature to help patients gain 
access to drugs, the brand name pharmaceutical manufacturers take their focus off the patients. 
Albeit the manufacturers’ shift in focus is only temporary, so, once the runtime period for 
legislation ends, the patient becomes the center of attention for both the legislation and the 
manufacturers. 
The topic model for the final period reveals topics mostly in line with the main words in 
the cloud. Although, a few new topics were introduced revealing new traits of brand name 
pharmaceutical manufacturers. Below are topics produced by the modeling software from the 
final period (See Appendix 2 for full topic model results): 
1. Metastatic Melanoma (lung cancer) 
2. Unmet Medical  
3. Emerging Markets/Consumer Healthcare  
4. Respect from Society/Trust 
5. United States 
6. Biopharma Company Long-term Success 
For the first time, brand name pharmaceutical manufacturers display a sense of self 
awareness and a more pronounced focus on long-term success. The new topic of respect and trust 
from society indicates top management focused attention towards external appearances and 
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perception for the first time. I hypothesize the shift is a result of both the Affordable Care Act 
and the Medicare Modernization Act failing to lower drug prices as expected and the following 
negative perception of the pharmaceutical industry by the public. A testament to the complex 
pharmaceutical supply chain’s ability to adapt to legislative change, the pharmaceutical 
manufacturers, as with legislation, quickly shifted attention and adapted to attempt to regain the 
public’s faith.  
The United States, unmet medical areas, and emerging consumer markets topics represent 
attention shifts taken by top management to restore public relations. By showing an attention 
shift and experimenting in new ways to expand customer markets and focus on the U.S.’s unmet 
needs, the manufacturers are now making tangible changes in line with management’s focus on 
growth via avenues that also appease the public. Playing into the dialogue of societally respectful 
growth, the topic of long-term success also shows the manufacturers now can more effectively 
strategically plan their business models without the burden of upcoming legislative change. 
Ultimately, without the presence of legislative change, top management focuses attention on 
appealing to the consumer and healthy, long-term growth instead of adapting to survive in new 
legislative landscapes.  
Comparison Across the Three Periods Using Dictionaries   
While the topic models and word frequency clouds gave good qualitative insights to the 
adaptations and strategies employed by pharmaceutical manufacturers, specialty business 
dictionaries for content analysis provide another way to identify broad changes undertaken by 
management across the three time periods. The dictionary analysis provides a word list for 
particular constructs. These word lists are then overlaid on the textual materials to provide 
frequency counts of words which can be used to statistically compare word frequencies across 
PHARMA MANUFACTURER’S REACTIONS TO HEALTHCARE LEGISLATION 30 
the three time periods. Instead of the computer program creating its own topics based on an 
algorithm of words in the letters, using dictionaries can show how topics changed from period to 
period and were statistically significant. The dictionary analysis is provided below in Figure 7. 
 
Figure 7: Dictionary frequency counts divided by total word count per page and resulting statistics 
noting statistical change over periods.  
 
The dictionary context analysis yielded interesting results both confirming and 
questioning some of the results from the topic models. Some of the dictionaries found no 
statistically significant change period to period, such as the organizational constructs of 
proactiveness, conscientiousness, and integrity, while others displayed significant change. The 
dictionary results mostly confirm the results of the topic models and word frequency clouds, and 
this is explained below  
Innovativeness showed the most significant change over the periods and reflects earlier 
hypothesizes about the firms transitioning to new healthy ways of growth instead of rapid growth 
to meet demands of new government programs. It also confirms the topics introduced in period 
three which focus on emerging markets and new ways to regain trust. Note the slow transition 
from period one to period three. The transition represents the tradeoff between government 
legislation change and the pharmaceutical manufacturers’ focus on innovation as the periods 
where change was introduced saw lower levels of innovation.   
Dictionaries 1 Frequency/Word Count 2
Frequency/Word 
Count 3
Frequency/Word 
Count Chi2 P (2-tails)
INNOVATIVENESS 72 0.318% 259 0.428% 455 0.561% 25.735 0.000
PROACTIVE 75 0.332% 159 0.263% 205 0.253% 4.308 0.116
RISKTAKING 9 0.040% 41 0.068% 89 0.110% 13.082 0.001
ORIENTATION COMPETITOR 79 0.349% 282 0.466% 340 0.419% 5.855 0.054
ORIENTATION CUSTOMER 44 0.195% 166 0.274% 188 0.232% 5.409 0.067
ORIENTATION INTERFIRM 107 0.473% 211 0.348% 412 0.508% 19.061 0.000
ORIENTATION LONG TERM FOCUS 157 0.694% 500 0.826% 754 0.929% 11.744 0.003
ORIENTATION PROFITS 103 0.455% 333 0.550% 384 0.473% 5.750 0.056
VIRTUE CONCIENTIOUSNESS 51 0.225% 149 0.246% 209 0.258% 0.675 0.714
VIRTUE INTEGRITY 15 0.066% 42 0.069% 54 0.067% 0.073 0.964
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Next, the interfirm statistic is another major confirmation of results from the topic models 
and frequency clouds. The interfirm dictionary returned a higher level of interfirm focus during 
the runtime for the Medicare Modernization Act followed by a drop after the legislation’s 
enactment and during the run time for the Affordable Care Act. The period one to two change 
represents the firms’ changing strategies for adapting to the Affordable Care Act and taking 
advantage of the Medicare Modernization Act. Lastly, the return of the interfirm focus in the 
third period likely represents the firms’ focus on regaining trust and establishing respect from 
society.  
Long-term focus and risk taking both saw statistically significant change over the 
periods, each with an increased focus every period. The dictionaries’ findings surrounding the 
two areas of focus agree largely with the discussion based off the topic models and frequency 
clouds. Risk taking changed period over period in line with the initially conservative approach to 
the Medicare Modernization Act, the rapid growth after, and the focus on emerging markets and 
unmet medical needs. The long-term focus, like in the topic models, appears to be most apparent 
in the latter periods.  
Lastly, the customer focus dictionary, while just missing statistical significance, does 
reflect a change over the periods. Conversely, the dictionary analysis seems to disagree with the 
last period having the strongest focus on the customer, favoring period two. However, I take the 
dictionary results hesitantly because the CEOs of major healthcare firms often do not use the 
word “customer” and instead use “patient” or “people.” Unfortunately, the words patient and 
people are not included in this dictionary. As a result, the unique vocabulary used by the brand 
name pharmaceutical manufacturers when referring to customers likely skewed the dictionary 
results, so the customer dictionary will be ignored for purposes of this study.  
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Summary Table of the Three Analyses’ Findings: 
Analysis 
Type: 
Entire Date 
Range: 
 
(2001-2018) 
Period 1:  
Pre-MMA 
 
(2001-2003) 
Period 2: 
Post-MMA/ 
Pre-ACA 
(2004-2009) 
Period 3: 
Post-ACA 
 
(2010-2018) 
Word 
Frequency 
Cloud (Top 
6 Words): 
Health, Care, 
Medicines, 
Products, 
People, and 
World 
Year, Company, 
Business, Products, 
World, and Sales 
Growth, Care, 
Health, Company, 
Medicines, and 
Products 
Patients, Year, 
Company, Health, 
Growth, and Medicines 
Topic 
Model: 
N/A 1. Worldwide Sales 
Operational 
Growth 
 
2. Research and 
Development 
 
3. Pharmaceutical 
Company and 
People 
 
4. Healthcare 
 
5. Key Leadership 
 
6. Food and Drug 
Administration 
Patents 
 
7. Financial 
Performance/C-
orporate 
Governance 
 
1. Stage Pipeline 
 
2. Sales Growth 
 
3. Unmet Medical 
Disease Areas 
 
4. Medical 
Devices 
 
5. Patients 
 
6. Research and 
Development 
 
7. Company 
Performance 
 
1. Metastatic 
Melanoma (lung 
cancer) 
 
2. Unmet Medical  
 
3. Emerging 
Markets/Consumer 
Healthcare  
 
4. Respect from 
Society/Trust 
 
5. United States 
 
6. Biopharma 
Company Long-term 
Success 
 
Dictionary: 
 
N/A Innovativeness: 
= 0.318% 
Risk taking: 
= 0.040% 
Interfirm: 
= 0.473% 
Long Term Focus: 
= 0.694% 
 
Innovativeness: 
= 0.428%  
Risk taking: 
= 0.068% 
Interfirm: 
= 0.348% 
Long Term Focus: 
= 0.826% 
Innovativeness: 
= 0.561% 
Risk taking: 
= 0.110% 
Interfirm: 
= 0.508% 
Long Term Focus: 
= 0.929% 
Overall 
Takeaways: 
 Firm’s focused 
primarily internally 
and on sales outside 
U.S. 
Firm’s focused 
primarily on rapid 
growth and new 
markets.  
Firm’s focused primarily 
on patients and long-
term success. 
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Conclusion 
U.S. pharmaceutical manufacturers operate in one of the most complex and ever-
changing industries in the world. With a lengthy supply chain passing through multiple 
“middlemen” parties, large brand name pharmaceutical companies have managed to survive, 
even prosper, during periods where their rules of operation change, and new legislation creates 
different markets. These firms’ ability to adapt to legislative changes in stride is remarkable, and 
they take great risks in doing so.  
The two largest pieces of healthcare legislation in U.S. history happened over the last two 
decades. The Medicare Modernization Act completely restructured public healthcare’s 
pharmaceutical drug policies and represented a large potential client for many pharmaceutical 
companies. Then, just six years later, the entire U.S. healthcare system was overhauled by the 
Affordable Care Act. So how do the pharmaceutical manufacturers stay ahead?  
In periods after a piece of legislation is announced and before enactment, large name 
brand pharmaceutical manufacturers quickly adapt. My study found few similarities between the 
run time before the Medicare Modernization Act and the Affordable Care Act, indicating 
manufacturers tailor adaptations specifically to each piece of legislation. For the Medicare 
Modernization Act, pharmaceutical manufacturers contracted by focusing internally on 
leadership and corporate governance. To ensure stability, they also focused on sales channels 
outside the U.S. For the Affordable Care Act, they focused more externally with top 
management’s attention set on rapid growth and expansion via expanding product lines and 
exploring unmet needs.  
Once the legislation changes ceased, the pharmaceutical manufacturers shifted to a more 
stable, healthy growth focus. The firms began to focus more on long-term success and rebuilding 
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their societal reputation. Resultantly, they focused on the U.S. market and continued to explore 
areas of unmet need. Overall, the manufacturers’ attention centered around their patients during 
times without legislative change and towards themselves during times of change.  
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Appendix 1 – Source of Organizational Dictionaries 
• EO – Innovativeness, Risk-taking, and Proactive Dictionaries 
o Developed by: Short, J. C., Broberg, J. C., Cogliser, C., & Brigham, K. H. 
(2010). Construct validation using computer-aided text analysis (CATA): 
an illustration using entrepreneurial orientation. Organizational Research 
Methods, 13, 320–347. 
• Market Orientation – Orientation Interfirm, Long Term Focus, Competitor, 
Profits, Customer 
o Developed by: Zachary, M. A., McKenny, A. F., Short, J. C., & Payne, G. 
T. (2011). Family business and market orientation: Construct validation 
and comparative analysis. Family Business Review, 24(3), 233-251. 
• Organization Virtue Orientation – Conscientiousness, Integrity 
o Developed by: Payne, G. T., Brigham, K. H., Broberg, J. C., Moss, T. W., 
& Short, J. C. (2011). Organizational virtue orientation and family firms. 
Business Ethics Quarterly, 21, 257-285. 
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Appendix 2 – Topic Model Results  
From Entire Period Studied (2001-2018): 
 
 
 
 
 
 
 
NO TOPICS - Entire Study Period KEYWORDS COHERENCE FREQ CASES % CASES
4 DILUTED EARNINGS PER SHARENET SALES
NET; DILUTED; ADJUSTED; PERCENT; SALES; INCOME; TOTAL; 
EARNINGS; GAAP; OPERATIONS; GREW; REVENUES; INCREASE; 
REPORTED; 
DILUTED EARNINGS PER SHARE; NET SALES; ADJUSTED 
EARNINGS; ADJUSTED EARNINGS PER SHARE; ADJUSTED 
DILUTED EARNINGS PER SHARE; CONTINUING OPERATIONS; NET 
INCOME; PERCENT INCREASE; PERCENT OPERATIONALLY; 
ADJUSTED INCOME; NET EARNINGS; SALES GREW; WORLDWIDE 
SALES; BILLION IN SALES; SALES GROWTH; TOTAL NET SALES; 
ADJUSTED COST OF SALES; PRODUCT SALES; SALES INCREASED; 
TOTAL SHAREHOLDER RETURN; 
0.456 610 64 91.43%
2 HIV AIDS
AIDS; HIV; AFRICA; INITIATIVE; CHILDREN; COMMUNITY; 
MILLION; ACCESS; FOUNDATION; 
HIV AIDS; SECURE THE FUTURE; LIVING WITH HIV; SAHARAN 
AFRICA; ACCESS PROGRAMS; INTERNATIONAL TRACHOMA 
INITIATIVE; MEDICINES FOR FREE; PEDIATRIC AIDS; PEOPLE 
LIVING; BLINDING TRACHOMA; RETURNING VETERANS; CHINA 
AND INDIA; MEDICAL CARE; 
0.450 289 52 74.29%
5 CLINICAL TRIALSLUNG CANCER
CLINICAL; PHASE; CANCER; STUDIES; MELANOMA; DATA; 
TREATMENT; TRIALS; LUNG; STAGE; ONCOLOGY; TYPE; LATE; 
DISEASE; STUDY; 
CLINICAL TRIALS; LUNG CANCER; STAGE PIPELINE; 
CARDIOVASCULAR DISEASE; CANCER PATIENTS; CLINICAL DATA; 
CLINICAL TRIAL; METASTATIC MELANOMA; PHASE ILL; BREAST 
CANCER; CLINICAL STUDIES; STAGE CLINICAL; CANCER 
TREATMENT; DISEASE AREAS; 
0.418 694 63 90.00%
3 MEDICAL DEVICES
DEVICES; DIAGNOSTICS; MEDICAL; SEGMENT; CARE; SURGICAL; 
CONSUMER; PHARMACEUTICALS; PRODUCTS; HEALTH; 
BUSINESSES; 
HEALTH CARE; MEDICAL DEVICES; MEDICAL DEVICES AND 
DIAGNOSTICS; CONSUMER HEALTHCARE; CONSUMER HEALTH; 
CARE PRODUCTS; HEALTH CARE BUSINESSES; CONSUMER 
HEALTH CARE; UNMET MEDICAL; GLOBAL HEALTH CARE; 
0.416 881 64 91.43%
7 UNITED STATES
UNITED; STATES; EUROPE; JAPAN; 
UNITED STATES; 
0.368 147 44 62.86%
6 OWNERSHIP CULTURE
INTEGRITY; CULTURE; TRUST; VALUES; LONG; CUSTOMERS; 
TERM; PEOPLE; COLLEAGUES; RESPECT; 
LONG TERM; OWNERSHIP CULTURE; MANAGING FOR THE LONG 
TERM; MILLIONS OF PEOPLE; RESPECT FROM SOCIETY; 
COMMITMENT TO INTEGRITY; STRONG VALUES; 
0.337 442 64 91.43%
1 THERAPEUTIC AREASDISCOVERY AND DEVELOPMENT
SCIENTIFIC; MANUFACTURING; THERAPEUTIC; DISCOVERY; 
MEDICINES; ANNOUNCED; 
DISCOVERY AND DEVELOPMENT; THERAPEUTIC AREAS; 
MEDICINES AND VACCINES; 
0.312 246 59 84.29%
PHARMA MANUFACTURER’S REACTIONS TO HEALTHCARE LEGISLATION 38 
From Period 1 (2001-2003): 
 
From Period 2 (2004-2009): 
 
NO TOPICS - Period 1 KEYWORDS COHERENCE FREQ CASES % CASES
5 WORLDWIDE SALESOPERATIONAL GROWTH
SALES; PERCENT; BILLION; GROWTH; STRONG; WORLDWIDE; 
MILLION; PRODUCT; 
NET SALES; OPERATIONAL GROWTH; WORLDWIDE SALES; SALES 
GROWTH; AVAPRO AVALIDE; SALES AND EARNINGS; CANCER 
TREATMENT; 
0.453 233 10 90.91%
2 RESEARCH AND DEVELOPMENTPHARMACEUTICAL COMPANIES
DEVELOPMENT; RESEARCH; COMPANIES; PHARMACEUTICAL; 
PIPELINE; 
RESEARCH AND DEVELOPMENT; PHARMACEUTICAL COMPANIES; 
0.401 140 11 100.00%
3 PHARMACEUTICAL COMPANYPEOPLE
PEOPLE; WORLD; COMPANY; YEARS; MILLION; GLOBAL; 
PHARMACEUTICAL COMPANY; VALUED COMPANY; HIV AIDS; 
0.388 178 11 100.00%
6 HEALTH CARE
CARE; HEALTH; MEDICAL; PRODUCTS; 
HEALTH CARE; CARE PRODUCTS; MEDICAL CARE; MEDICAL 
DEVICES; SKIN CARE; BROADLY BASED; 
0.385 136 10 90.91%
7 KEYLEADERSHIP KEY; LEADERSHIP; LEADERS; FUTURE; BUSINESS; GLOBAL; 0.383 119 11 100.00%
1
FOOD AND DRUG 
ADMINISTRATION
PATIENTS
PATIENTS; IMPORTANT; DRUG; TREATMENT; MEDICINES; 
FOOD AND DRUG ADMINISTRATION; UNITED STATES; 
0.373 116 11 100.00%
4 FINANCIAL PERFORMANCECORPORATE GOVERNANCE
PERFORMANCE; FINANCIAL; YEAR; CORPORATE; 
FINANCIAL PERFORMANCE; CONSECUTIVE YEAR; CORPORATE 
GOVERNANCE; 
0.367 128 11 100.00%
NO TOPIC - Period 2 KEYWORDS COHERENCE FREQ CASES % CASES
6 STAGE PIPELINE
STAGE; LATE; COMPOUNDS; DEVELOPMENT; APPROVAL; 
PIPELINE; REVIEW; FDA; REGULATORY; CLINICAL; CANCER; 
POTENTIAL; FULL; 
CLINICAL TRIALS; STAGE PIPELINE; FULL DEVELOPMENT; 
REGULATORY APPROVAL; STAGE CLINICAL; STAGE 
DEVELOPMENT; PHASE III; ANNUAL REVIEW; REGULATORY 
AUTHORITIES; PHARMACEUTICAL PIPELINE; REGULATORY 
REVIEW; 
0.492 315 24 100.00%
5 SALES GROWTHBILLION
BILLION; SALES; PERCENT; TOTAL; EARNINGS; ADJUSTED; 
REVENUE; LINE; GROWTH; YEAR; INCREASED; DELIVERED; 
SALES GROWTH; ADJUSTED EARNINGS PER SHARE; CONTINUING 
OPERATIONS; 
0.446 465 24 100.00%
3 UNMET MEDICALDISEASE AREAS
AREAS; UNMET; DISEASE; INNOVATIVE; MEDICAL; THERAPEUTIC; 
DISEASES; SIGNIFICANT; BUILDING; STRATEGY; 
UNMET MEDICAL; DISEASE AREAS; THERAPEUTIC AREAS; 
INNOVATIVE MEDICINES; AREAS OF SIGNIFICANT; 
CARDIOVASCULAR DISEASE; SIGNIFICANT UNMET MEDICAL; 
PATIENTS PREVAIL; 
0.433 259 22 91.67%
4 MEDICAL DEVICES
DEVICES; DIAGNOSTICS; MEDICAL; CONSUMER; 
PHARMACEUTICALS; CARE; BUSINESSES; HEALTH; 
HEALTH CARE; MEDICAL DEVICES; MEDICAL DEVICES AND 
DIAGNOSTICS; CONSUMER HEALTH; CONSUMER HEALTH CARE; 
HEALTH CARE BUSINESSES; BROADLY BASED; HEALTH CARE 
PRODUCTS; 
0.428 369 21 87.50%
7 PATIENTS
PATIENTS; MEDICINE; MEDICINES; SAFETY; PATIENT; CLINICAL; 
WORLD; APPROVED; INDUSTRY; PEOPLE; MILLION; WORK; 
MILLIONS OF PEOPLE; CLINICAL TRIALS; PEOPLE AROUND THE 
WORLD; CLINICAL DATA; CLINICAL TRIAL; 
0.405 478 24 100.00%
2 RESEARCH AND DEVELOPMENTMANUFACTURING
MANUFACTURING; PRODUCTIVITY; GLOBAL; RESEARCH; COST; 
RESOURCES; DEVELOPMENT; LARGE; MARKETS; 
RESEARCH AND DEVELOPMENT; EMERGING MARKETS; GLOBAL 
RESEARCH; COST BASE; BIOMEDICAL RESEARCH; COST SAVINGS; 
0.364 214 23 95.83%
1 COMPANYPERFORMANCE
COMPANY; PERFORMANCE; MISSION; COMMITMENT; FUTURE; 
LONG; CUSTOMERS; PAST; MAKE; HEALTH; CHANGE; FINANCIAL; 0.360 397 24 100.00%
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From Period 3 (2010-2018): 
 
NO TOPIC - Period 3 KEYWORDS COHERENCE FREQ CASES % CASES
4 PERCENT INCREASE
PERCENT; BILLION; ADJUSTED; DIVIDEND; SALES; INCREASE; 
TOTAL; CASH; RETURN; GREW; APPROXIMATELY; SHARE; 
INCREASED; OPERATIONAL; YEAR; 
SHAREHOLDER RETURN; PERCENT INCREASE; BILLION IN SALES; 
CASH FLOW; PERCENT OPERATIONALLY; TOTAL SHAREHOLDER 
RETURN; DIGIT GROWTH; ADJUSTED DILUTED EARNINGS PER 
SHARE; ADJUSTED EARNINGS PER SHARE; CONSECUTIVE YEAR; 
SHARE REPURCHASES; SALES GREW; ADJUSTED COST OF SALES; 
ADJUSTED INCOME; BILLION TO SHAREHOLDERS; INCREASED 
OUR DIVIDEND; INFORMATIONAL AND ADMINISTRATIVE 
EXPENSES; PREVIOUS YEAR; 
0.452 516 35 100.00%
5 METASTATIC MELANOMA
MELANOMA; CLINICAL; LINE; DATA; STUDIES; LUNG; PHASE; 
IMMUNO; COMBINATION; ONCOLOGY; TREATMENT; CANCER; 
POSITIVE; THERAPY; 
LUNG CANCER; METASTATIC MELANOMA; CANCER PATIENTS; 
TUMOR TYPES; CLINICAL DATA; CLINICAL TRIAL; CLINICAL 
TRIALS; IMMUNE SYSTEM; CLINICAL STUDIES; ONCOLOGY 
PORTFOLIO; 
0.429 353 31 88.57%
2 UNMET MEDICALMOLECULES
UNMET; MOLECULES; MEDICAL; PIPELINE; DISEASE; STAGE; 
AREAS; EARLY; THERAPEUTIC; ADVANCING; POTENTIAL; 
CARDIOVASCULAR; PHASE; DEVELOPMENT; RESEARCH; 
UNMET MEDICAL; STAGE PIPELINE; THERAPEUTIC AREAS; 
RESEARCH AND DEVELOPMENT; CARDIOVASCULAR DISEASE; 
SIGNIFICANT UNMET; AREAS OF HIGH UNMET MEDICAL; 
SIGNIFICANT UNMET MEDICAL; 
0.406 454 34 97.14%
1 EMERGING MARKETSCONSUMER HEALTHCARE
MARKETS; EMERGING; CONSUMER; PHARMACEUTICALS; 
BUSINESSES; PRODUCTS; BRANDS; GROWTH; KEY; BUSINESS; 
OPERATIONAL; 
EMERGING MARKETS; CONSUMER HEALTHCARE; GROWTH IN 
EMERGING MARKETS; PHARMACEUTICALS BUSINESS; CONSUMER 
HEALTHCARE BUSINESS; INNOVATIVE PRODUCTS; CONSUMER 
BUSINESS; ANIMAL HEALTH; KEY PRODUCTS; MARKETS AROUND 
THE WORLD; STRONG GROWTH; 
0.397 412 35 100.00%
3 RESPECT FROM SOCIETYTRUST
TRUST; RESPECT; INTEGRITY; SOCIETY; CULTURE; INITIATIVE; 
LIVES; COLLEAGUES; PEOPLE; 
OWNERSHIP CULTURE; RESPECT FROM SOCIETY; GREATER 
RESPECT; GREATER RESPECT FROM SOCIETY; 
0.387 209 31 88.57%
6 UNITED STATES
UNITED; STATES; EUROPE; PREVENTION; 
UNITED STATES; 
0.384 73 22 62.86%
7 BIOPHARMA COMPANYTERM SUCCESS
TERM; LONG; BIOPHARMA; COMPANY; FUTURE; 
BIOPHARMA COMPANY; LONG TERM; TERM GROWTH; TERM 
SUCCESS; 
0.330 256 34 97.14%
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Appendix 3 – Exclusion Words (high frequency words) 
A 
ABLE 
ABOUT 
ABOVE 
ACCORDING 
ACCORDINGLY 
ACROSS 
ACTUALLY 
AFTER 
AFTERWARDS 
AGAIN 
AGAINST 
AIN'T 
ALL 
ALLOW 
ALLOWS 
ALMOST 
ALONE 
ALONG 
ALREADY 
ALSO 
ALTHOUGH 
ALWAYS 
AM 
AMGEN 
AMONG 
AMONGST 
AN 
AND 
ANNUAL_REPOR
T 
ANOTHER 
ANY 
ANYBODY 
ANYHOW 
ANYONE 
ANYTHING 
ANYWAY 
ANYWAYS 
ANYWHERE 
APART 
APPEAR 
APPRECIATE 
APPROPRIATE 
ARE 
AREN'T 
AROUND 
AS 
ASIDE 
ASK 
ASKING 
ASSOCIATED 
AT 
AVAILABLE 
AWAY 
AWFULLY 
B 
BACK 
BE 
BECAME 
BECAUSE 
BECOME 
BECOMES 
BECOMING 
BEEN 
BEFORE 
BEFOREHAND 
BEHIND 
BEING 
BELIEVE 
BELOW 
BESIDE 
BESIDES 
BEST 
BETTER 
BETWEEN 
BEYOND 
BOARD 
BOARD_OF_DIR
ECTORS 
BOTH 
BRIEF 
BRISTOL 
BUT 
BY 
C 
CAME 
CAN 
CANNOT 
CANT 
CAN'T 
CAUSE 
CAUSES 
CEO 
CERTAIN 
CERTAINLY 
CHAIRMAN 
CHAIRMAN_AN
D_CEO 
CHAIRMAN_AN
D_CHIEF_EXECU
TIVE_OFFICER 
CHAIRMAN_OF_
THE_BOARD 
CHANGES 
CHIEF_EXECUTI
VE_OFFICER 
CLEARLY 
C'MON 
CO 
COM 
COME 
COMES 
COMMITTEE 
CONCERNING 
CONSEQUENTLY 
CONSIDER 
CONSIDERING 
CONTAIN 
CONTAINING 
CONTAINS 
CORRESPONDIN
G 
COULD 
COULDN'T 
COURSE 
C'S 
CURRENTLY 
D 
DEFINITELY 
DESCRIBED 
DESPITE 
DID 
DIDN'T 
DIFFERENT 
DIRECTOR 
DIRECTORS 
DO 
DOES 
DOESN'T 
DOING 
DONE 
DON'T 
DOWN 
DOWNWARDS 
DUE 
DURING 
E 
EACH 
EARNINGS_PER_
SHARE 
EDU 
EG 
EIGHT 
EITHER 
ELIQUIS 
ELSE 
ELSEWHERE 
ENBREL 
ENOUGH 
ENTIRELY 
ESPECIALLY 
ET 
ETC 
EVEN 
EVER 
EVERY 
EVERYBODY 
EVERYONE 
EVERYTHING 
EVERYWHERE 
EX 
EXACTLY 
EXAMPLE 
EXCEPT 
EXECUTIVE_VIC
E_PRESIDENT 
F 
FAR 
FEW 
FIFTH 
FIND 
FIRST 
FIVE 
FOLLOWED 
FOLLOWING 
FOLLOWS 
FOR 
FORMER 
FORMERLY 
FORTH 
FOUND 
FOUR 
FROM 
FURTHER 
FURTHERMORE 
G 
GET 
GETS 
GETTING 
GIVE 
GIVEN 
GIVES 
GO 
GOES 
GOING 
GONE 
GOT 
GOTTEN 
GREETINGS 
H 
HAD 
HADN'T 
HAPPENS 
HARDLY 
HAS 
HASN'T 
HAVE 
HAVEN'T 
HAVING 
HE 
HELLO 
HELP 
HENCE 
HER 
HERE 
HEREAFTER 
HEREBY 
HEREIN 
HERE'S 
HEREUPON 
HERS 
HERSELF 
HE'S 
HI 
HIM 
HIMSELF 
HIS 
HITHER 
HOPEFULLY 
HOW 
HOWBEIT 
HOWEVER 
I 
I'D 
IE 
IF 
IGNORED 
I'LL 
I'M 
IMMEDIATE 
IN 
INASMUCH 
INC 
INDEED 
INDEPENDENT 
INDEPENDENT_
DIRECTORS 
INDICATE 
INDICATED 
INDICATES 
INNER 
INSOFAR 
INSTEAD 
INTO 
INWARD 
IS 
ISN'T 
IT 
IT'D 
IT'LL 
ITS 
IT'S 
ITSELF 
I'VE 
J 
JOHNSON 
JUST 
K 
KEEP 
KEEPS 
KEPT 
KNOW 
KNOWN 
KNOWS 
L 
LAST 
LATELY 
LATER 
LATTER 
LATTERLY 
LEAD_INDEPEN
DENT_DIRECTO
R 
LEAST 
LESS 
LEST 
LET 
LET'S 
LIKE 
LIKED 
LIKELY 
LITTLE 
LOOK 
LOOKING 
LOOKS 
LTD 
M 
MADE 
MAINLY 
MANY 
MAY 
MAYBE 
ME 
MEAN 
MEANWHILE 
MERELY 
MIGHT 
MINE 
MORE 
MOREOVER 
MOST 
MOSTLY 
MUCH 
MUST 
MY 
MYERS 
MYSELF 
N 
NAME 
NAMELY 
ND 
NEAR 
NEARLY 
NECESSARY 
NEED 
NEEDS 
NEITHER 
NEULASTA 
NEVER 
NEVERTHELESS 
NEW 
NEXT 
NINE 
NO 
NOBODY 
NON 
NONE 
NOONE 
NOR 
NORMALLY 
NOT 
NOTHING 
NOVEL 
NOW 
NOWHERE 
O 
OBVIOUSLY 
OF 
OFF 
OFTEN 
OH 
OK 
OKAY 
OLD 
ON 
ONCE 
ONE 
ONES 
ONLY 
ONTO 
OPDIVO 
OR 
OTHER 
OTHERS 
OTHERWISE 
OUGHT 
OUR 
OURS 
OURSELVES 
OUT 
OUTSIDE 
OVER 
OVERALL 
OWN 
P 
PARTICULAR 
PARTICULARLY 
PER 
PERHAPS 
PFIZER 
PLACED 
PLAVIX 
PLEASE 
PLUS 
POSSIBLE 
PRESUMABLY 
PROBABLY 
PROLIA 
PROVIDES 
PUT 
Q 
QUE 
QUITE 
QV 
R 
RATHER 
RD 
RE 
REALLY 
REASONABLY 
REGARDING 
REGARDLESS 
REGARDS 
RELATIVELY 
REPATHA 
RESPECTIVELY 
RIGHT 
S 
SAID 
SAME 
SAW 
SAY 
SAYING 
SAYS 
SECOND 
SECONDLY 
SEE 
SEEING 
SEEM 
SEEMED 
SEEMING 
SEEMS 
SEEN 
SELF 
SELVES 
SENSIBLE 
SENT 
SERIOUS 
SERIOUSLY 
SEVEN 
SEVERAL 
SHALL 
SHE 
SHOULD 
SHOULDN'T 
SINCE 
SIX 
SO 
SOME 
SOMEBODY 
SOMEHOW 
SOMEONE 
SOMETHING 
SOMETIME 
SOMETIMES 
SOMEWHAT 
SOMEWHERE 
SOON 
SORRY 
SPECIFIED 
SPECIFY 
SPECIFYING 
SQUIBB 
STILL 
SUB 
SUCH 
SUP 
SURE 
T 
TAKE 
TAKEN 
TELL 
TENDS 
TH 
THAN 
THANK 
THANKS 
THANX 
THAT 
THATS 
THAT'S 
THE 
THEIR 
THEIRS 
THEM 
THEMSELVES 
THEN 
THENCE 
THERE 
THEREAFTER 
THEREBY 
THEREFORE 
THEREIN 
THERES 
THERE'S 
THEREUPON 
THESE 
THEY 
THEY'D 
THEY'LL 
THEY'RE 
THEY'VE 
THINK 
THIRD 
THIS 
THOROUGH 
THOROUGHLY 
THOSE 
THOUGH 
THREE 
THROUGH 
THROUGHOUT 
THRU 
THUS 
TO 
TOGETHER 
TOO 
TOOK 
TOWARD 
TOWARDS 
TRIED 
TRIES 
TRULY 
TRY 
TRYING 
T'S 
TWICE 
TWO 
U 
UN 
UNDER 
UNFORTUNATEL
Y 
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UNLESS 
UNLIKELY 
UNTIL 
UNTO 
UP 
UPON 
US 
USE 
USED 
USEFUL 
USES 
USING 
USUALLY 
UUCP 
V 
VALUE 
VARIOUS 
VERY 
VIA 
VICE_PRESIDEN
T 
VIZ 
VS 
W 
WANT 
WANTS 
WAS 
WASN'T 
WAY 
WE 
WE'D 
WELCOME 
WELL 
WE'LL 
WENT 
WERE 
WE'RE 
WEREN'T 
WE'VE 
WHAT 
WHATEVER 
WHAT'S 
WHEN 
WHENCE 
WHENEVER 
WHERE 
WHEREAFTER 
WHEREAS 
WHEREBY 
WHEREIN 
WHERE'S 
WHEREUPON 
WHEREVER 
WHETHER 
WHICH 
WHILE 
WHITHER 
WHO 
WHOEVER 
WHOLE 
WHOM 
WHO'S 
WHOSE 
WHY 
WILL 
WILLING 
WISH 
WITH 
WITHIN 
WITHOUT 
WONDER 
WON'T 
WOULD 
WOULDN'T 
X 
Y 
YERVOY 
YES 
YET 
YOU 
YOU'D 
YOU'LL 
YOUR 
YOU'RE 
YOURS 
YOURSELF 
YOURSELVES 
YOU'VE 
Z 
ZERO 
 
